Medicago Inc.
TSX VENTURE : MDG

Medicago Inc.

May 07, 2008 08:00 ET

Medicago Appoints New VP Manufacturing

QUEBEC CITY, QUEBEC--(Marketwire - May 7, 2008) - Medicago Inc. (TSX VENTURE:MDG) today announced that Brigitte Barbeau has been appointed Vice President, Manufacturing, and is expected to join the company on May 26, 2008. In this newly created position, Ms. Barbeau will lead the Company's manufacturing functions to accelerate the development of Medicago's H5N1 pandemic influenza vaccine and other vaccine candidates.

"We are delighted to welcome Brigitte to Medicago. Our ability to attract an individual with a high level of experience from a leading pharmaceutical company is a testimony of the value people recognize in Medicago," said Andy Sheldon, President and CEO of Medicago. "Brigitte has special experience in the commercial production of influenza vaccines as a result of her work with GlaxoSmithKline Biologicals. Furthermore, with over 20 years of development, quality system design and quality assurance experience, along with expertise in immunology and virology, she will play a significant role in the further expansion of our manufacturing capabilities as we advance the commercialization of our H5N1 VLP vaccine."

Ms. Barbeau commented, "Medicago is pioneering the development of an innovative solution for the production of influenza vaccines which has, in my opinion, the potential to significantly improve speed and costs of current influenza vaccine manufacturing technologies. I look forward to contributing to the advancement of this technology and its subsequent commercialization."

Since 2006, Ms. Barbeau has served as Quality Assurance ("QA") and Quality Control ("QC") Director at GlaxoSmithKline Biologicals. She led a 200 member team and was responsible for the functions of quality control analytical validation and stability, quality assurance, compliance and document control in both Laval and Ste-Foy influenza production facilities. From 2002 to 2006, Ms. Barbeau served as QC Director at Shire and ID Biomedicals. Prior to Shire, Ms. Barbeau was at Galderma Production Canada in 2001, Biomatrix Medical Canada from 1998 to 2001 and Biochem ImmunoSystems from 1989 to 1998. Ms. Barbeau holds a B.S in Biology from Sherbrooke University.

About Medicago Inc.

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants.

This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain.

This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward-Looking Statements

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange assumes no responsibility for the content or accuracy of this press release

Contact Information

  • Medicago Inc.
    Andy Sheldon
    President and CEO
    418-658-9393
    or
    The Equicom Group Inc.
    Arianna Vanin
    Investor Relations
    514-844-4680
    avanin@equicomgroup.com